Clinical Trial Update: A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of GLPG3667 for dermatomyositis is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• GLPG3667

Snippet

Sponsor: Galapagos NV | Conditions: Dermatomyositis | Phase 2 | Status: ACTIVE_NOT_RECRUITING